<table>
<thead>
<tr>
<th>Day</th>
<th>Program Slots</th>
<th>Day 1 Thursday 12/9/10</th>
<th>Day 2 Friday 12/10/10</th>
<th>Day 3 Saturday 12/11/10</th>
<th>Day 4 Sunday 12/12/10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday 12/8/10</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7:00</td>
<td>7:30</td>
<td>8:00</td>
<td>8:15</td>
<td>8:30</td>
<td>8:45</td>
</tr>
<tr>
<td>8:45</td>
<td>9:00</td>
<td>9:15</td>
<td>9:30</td>
<td>9:45</td>
<td>10:00</td>
</tr>
<tr>
<td>10:15</td>
<td>10:30</td>
<td>10:45</td>
<td>11:00</td>
<td>11:15</td>
<td>11:30</td>
</tr>
<tr>
<td>11:45</td>
<td>12:00</td>
<td>12:15</td>
<td>12:30</td>
<td>12:45</td>
<td>1:00</td>
</tr>
<tr>
<td>1:15</td>
<td>1:30</td>
<td>1:45</td>
<td>2:00</td>
<td>2:15</td>
<td>2:30</td>
</tr>
<tr>
<td>2:45</td>
<td>3:00</td>
<td>3:15</td>
<td>3:30</td>
<td>3:45</td>
<td>4:00</td>
</tr>
<tr>
<td>4:15</td>
<td>4:30</td>
<td>4:45</td>
<td>5:00</td>
<td>5:15</td>
<td>5:30</td>
</tr>
<tr>
<td>5:45</td>
<td>6:00</td>
<td>6:15</td>
<td>6:30</td>
<td>6:45</td>
<td>7:00</td>
</tr>
<tr>
<td>7:15</td>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**SCHEDULE AT A GLANCE**

**Welcome**

**Plen - Metabolomics-Dang**

**General Session 1**

**Outstdg Invstgr**

**Lunch 12:00-1:35**

**Basic - Dormancy**

**Clin - Screening**

**Mini Symposium 1**

**Non-coding RNAs**

**General Session 2**

**Komen Brinker Lectures**

**Poster Session 1**

**Poster Disc 1**

**Poster Disc 2**

**Year in Review Lectures**

**Basics - Fuqua**

**Transl - Dowsett**

**Early - Goldhirsch**

**Late - Carey**

**General Session 4**

**Poster Session 4**

**Poster Disc 7**

**Poster Disc 8**

**General Session 5**

**AACR Lecture Ashworth**

**McGuire Lecture Sledge**

**Lunch 12:00-1:35**

**Basic - Stem Cells**

**Clin Case Disc**

**Mini Symposium 2**

**Surgical Topics**

**Poster Session 3**

**Poster Disc 5**

**Poster Disc 6**

**General Session 6**

**Mini Symposium 3**

**Disparities**

For Exhibit Hours See Page ??
Wednesday, December 8, 2010

12:00-7:00 Registration – Bridge Hall
Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

2:00-7:30 Educational Sessions – Ballroom Level – Ballroom C
An update on advances in the technologies available for translational research. Sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies.

2:00-3:30 Educational Session
CNS Metastases in Breast Cancer: Current Challenges and Future Directions – Ballroom C-1
Moderator: Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Advances in neurosurgery in the management of CNS metastases
Elizabeth B. Claus, MD, PhD
Yale University
New Haven, CT

Radiation therapy for CNS metastases: What should the standard approach be?
Minesh P. Mehta, MD
University of Wisconsin School of Medicine and Public Health
Madison, WI

Systemic therapy for CNS metastases
Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Translating new approaches from bench to bedside
Patricia S. Steeg, PhD
National Cancer Institute
Bethesda, MD

Panel Discussion

2:00-3:30 Educational Session
The Clinical Utility of Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond – Ballroom C-2
Moderator: Mark E. Robson, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Evaluation of breast cancer predisposition in different clinical venues
Sharon E. Plon, MD, PhD
Baylor College of Medicine
Houston, TX

3:30-4:00 Panel Discussion

4:00-5:30 Educational Session
DNA Repair – Ballroom C-3
Moderator: Daniel P. Silver, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

DNA repair pathways and tumorigenesis
James M. Ford, MD
Stanford University Medical Center
Stanford, CA

DNA repair and breast cancer: Therapeutic opportunities and challenges
Daniel P. Silver, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

4:00-5:30 Educational Session
Design & Interpretation of Biomarker Studies – Ballroom C-1
Moderator: Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM

Statistical challenges in predictive and prognostic biomarker studies: How to avoid wasting your time and specimens
Lisa M. McShane, PhD
National Cancer Institute
Bethesda, MD

The importance of technical validation
Jorge Reis-Filho, MD, PhD, MRCPath
Breakthrough Breast Cancer Research Center
The Institute of Cancer Research
London, UNITED KINGDOM

Interpretation of biomarker studies
Lajos Pusztai, MD, DPhil
Breakthrough Breast Cancer Research Center
The Institute of Cancer Research
London, UNITED KINGDOM

4:00-5:30 Educational Session
Emerging Radiation Techniques – The Fast and the Furious – Ballroom C-2
Moderator: Richard Crownover, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

Rationale and results of accelerated partial breast irradiation
Frank A. Vicini, MD, FACR
William Beaumont Hospital
Royal Oak, MI

Radiosurgery and stereotactic body radiotherapy
Richard Crownover, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

4:00-5:30 Educational Session
Automated, Quantitative Cell and Tissue Imaging Technologies – Ballroom C-3
Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX
Measuring and modeling cell death pathways in tumor cells
Peter K. Sorger, PhD
Harvard Medical School
Boston, MA

Quantitative methods to assess eligibility for breast cancer therapy
David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT

6:00-7:30 Educational Session
Next Generation Sequencing for the Clinician – Ballroom C-1
Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

- Next-generation sequencing and analysis of tumor/normal pairs
  Elaine R. Mardis, PhD
  Washington University
  St. Louis, MO

- Leveraging next generation sequencing in the study of breast cancer somatic genetics
  Andrew Futreal, PhD
  Wellcome Trust Sanger Institute
  Cambridge, UNITED KINGDOM

6:00-7:30 Educational Session
Next Generation Sequencing for the Clinician – Ballroom C-1
Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

- Next-generation sequencing and analysis of tumor/normal pairs
  Elaine R. Mardis, PhD
  Washington University
  St. Louis, MO

- Leveraging next generation sequencing in the study of breast cancer somatic genetics
  Andrew Futreal, PhD
  Wellcome Trust Sanger Institute
  Cambridge, UNITED KINGDOM

- Leveraging next generation sequencing in the study of breast cancer somatic genetics
  Andrew Futreal, PhD
  Wellcome Trust Sanger Institute
  Cambridge, UNITED KINGDOM

6:00-7:30 Educational Session
Next generation sequencing for gene expression profiling
Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

7:00-8:30 Career Development Forum: A Networking Session for Young Investigators – Ballroom B
Networking and career development opportunities for early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 135 participants; registrations will be accepted on a first-come, first-served basis and is free of charge. Please complete the registration form on page ??, Discussion topics include Careers in Government; Careers in Industry, Careers in Translational Research, Grant Writing – Basic/Translational, Grant Writing – Clinical, How to Get the Most Out of Your Fellowship Years, How to Make the Most Out of Being A Cooperative Group Member, Making the Transition to Independence, Mentoring and Supervising, Negotiating a Job Offer or Promotion, Oral Presentation Skills, Publication Strategies, Searching for a Job and Interviewing, Setting Up and Managing a Laboratory, The Path Leading to Clinical Trials

8:30-8:45 WELCOME – Exhibit Hall D
Opening Remarks
C. Kent Osborne, MD
Peter M. Ravdin, MD, PhD

8:45-9:15 PLENARY LECTURE 1 – Exhibit Hall D
Metabolic Reprogramming of Cancer Cells and Therapeutic Opportunities
Chi Van Dang, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD
11. Final analysis of NCIC CTG MA.27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer
Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Massachusetts General Hospital, Boston, MA, Mayo Clinic, Rochester, MN, Queen’s University, Kingston, ON, Canada, Washington University, St Louis, MO, Indiana University Simon Cancer Center, Indianapolis, Cleveland Clinic, OH, University Institute of Medical Oncology Inselspital, Berne, Switzerland, Dutch Cancer Society, Amsterdam, NL, University of Melbourne, Melbourne, Victoria, Australia, University of California, Los Angeles, CA, Memorial Sloan Kettering Cancer Center, New York, NY, Dana-Farber Cancer Institute, Boston, MA, Mayo Clinic, Rochester, MN, Duke University, Durham, NC, University of North Carolina, Chapel Hill, University of Texas, Houston.

ACOSOG Z1031: A randomized neoadjuvant comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EEX) for postmenopausal women with ER Rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype

13. A comparison of Fulvestrant 500 mg with Anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the ‘FIRST’ study
Robertson JFR, Lindemann JPD, Llombart-Cussac A, Rolski J, Felt D, Dewar J, Emerson L, Dean A, Ellis MJ. University of Nottingham, United Kingdom, AstraZeneca, United Kingdom, Hospital Arnau de Vilanova, Lleida, Spain, Centrum Instytut im M, Sklodowskiej-Curie, Krakow, Poland, FN Ostrava, Ostrave, Czech Republic, Ninewells Hospital and Medical School, Dundee, United Kingdom, Washington University School of Medicine, St Louis.

14. A randomized, placebo-controlled, phase 2 study of AMG 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) locally advanced (LA) or metastatic (M) breast cancer (BC)

15. Interaction between Goserelin and Tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer
Svensdottr A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist LE, Fornander T. Karolinska Institutet and University Hospital, Stockholm, Sweden, Lundspital University Hospital, Reykjavik, Iceland, School of Cancer & Enabling Sciences, University of Manchester & Paterson Institute, Medical Oncology Breast Unit, Christie Hospital, Manchester, United Kingdom.

16. TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI)
21. Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer

22. Multivariate analysis of obesity and disease free survival in patients with nodal positive primary breast cancer - The ADEBAR trial

23. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study
Seuynaev C, Hille E, Hasenburg A, Rea D, Markopolous C, Hozumi Y, Putter H, Nortier H, van Nes J, Dirix L, van de Velde C. Erasmus MC, University Medical Center, Rotterdam, Netherlands, Leiden University Medical Center, Netherlands, University Hospital Freiburg, Germany. The University of Birmingham, United Kingdom, Athens University Medical School, Athens, Greece, Jichi Medical University, Shimotsuke, Japan, Sint Augustinus, Wilrijk, Belgium.

24. Final results of a prospectively planned biomarker analysis versus Tamoxifen in the TEAM pathology sub-study
Bartlett JMS, Brookes CL, van de Velde CJH, Stocken D, Campbell FM, Hasenburg A, Kay C, Kiebeck D, Markopolous C, Meershoek-Klein Kranenborg E, Mallon EA, Dirix L, Robson T, Seuynaev C, Rea DW. University of Edinburgh, United Kingdom, University of Birmingham, United Kingdom, Leiden University Medical Centre, Netherlands, University Hospital, Freiburg, Germany, Helios Medical Centre, Aue, Germany, Athens University Medical School, Athens, Greece, Western Infirmary, Glasgow, United Kingdom, Az Augustinus, Antwerp, Belgium, Erasmus MC, Rotterdam, Netherlands.

25. Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumours identifies determinants of response
33. First results of the NeoALTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER2-positive primary breast cancer

Baselga J, Bradbury J, Eitdmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinl P, Fauria K, Van Dooren V, Paletto P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M, On behalf of the NeoALTO Study Team. Vall d’Hebron University Hospital, Barcelona, Spain, FISS Ltd, Kincraig, United Kingdom, University Hospital Kiel, Germany, Breast Cancer Center Vall d’Hebron University Hospital and SOLTI (Spanish Breast Cancer Research Group), Barcelona, Spain, Institut Jules Bordet and Breast European Adjutant Study Team, Brussels, Belgium, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, Breast International Group, Brussels, Belgium, SOLTI (Spanish Breast Cancer Research Group), Barcelona, Spain, Breast European Adjutant Study Team, Brussels, Belgium, GlaxoSmithKline, Collegeville, PA, European Institute of Oncology, Milan, Italy, National Cheng Kung University Hospital, Tainan, Taiwan, National Institute of Oncology, Budapest, Hungary, Academic Hospital of the University Charite, Berlin, Germany, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Institut Jules Bordet, Brussels, Belgium.

34. Discussion
Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA

35. Discordance in hormone receptor and HER2 status in breast cancer during tumor progression
Lindstrom LS, Karlsson E, Wilking U, Bergh J. Karolinska Institute, Stockholm, Sweden; Karlstad Hospital, Karlstad, Sweden.

36. Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with Trastuzumab-DM1 antibody drug conjugate enhances anti-tumor activity in preclinical breast cancer models in vitro and in vivo

37. Kinome screening for regulators of estrogen receptor identifies a novel kinase as a new therapeutic target in breast cancer
Giamas G, Filipovic A, Jacob J, Shiha BA, Green AR, Ellis IO, Lenz H-J, Stebbing J. Imperial College, London, United Kingdom, Queen’s Medical Centre, Nottingham University Hospital, Nottingham, United Kingdom, University of Southern California, Norris Comprehensive Cancer Centre, Keck School of Medicine, Los Angeles, CA.

38. RNAi screening identifies the insulin/insulin-like growth factor-I receptor pathway as a mechanism of escape from hormone dependence in estrogen receptor-positive breast cancer
Fox EM, Miller TW, Ye F, Shyr Y, Arteaga CL. Vanderbilt- Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, TN.

3.1. Lapatinib vs Trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44)

3.2. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study (‘NeoSphere’)
Gian L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A, Semiglavov V, Szado T, Ross G. Istituto Nazionale Tumori, Milan, Italy, Centrum Onkologii, Warsaw, Poland, Samsung Medical Center, Seoul, Korea, Leningrad Regional Oncology Dispensary, St. Petersburg, Russian Federation, Taipei Veterans General Hospital, Taiwan, Kao Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, Hospital Clinico Universitario, Valencia, Spain, NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation, ROCHE Products Limited, Welwyn, United Kingdom
Cancers are stressed too: exploiting cancer stress for new therapies
Garth Powis, D.Phil.
UT MD Anderson Cancer Center
Houston, TX

Molecular chaperones: Cancer dependence and druggability
Paul Workman, PhD, DSc (Hon), FMedSci FSB
Cancer Research UK Centre of Cancer Therapeutics
The Institute Of Cancer Research
Sutton, UNITED KINGDOM

1:45-2:45 MINI-SYMPOSIUM 2 – Exhibit Hall D
Surgery
Moderator: Ismail Jatoi, MD, PhD, FACS
UT Health Science Center San Antonio
San Antonio, TX

Surgical considerations in early-stage breast cancer
Lisa A. Newman, MD, MPH, FACS
University of Michigan Medical School
Ann Arbor, MI

Recent U.S. trends in the local treatment of primary breast cancer
Todd M. Tuttle, MD, MPH
University of Minnesota
Minneapolis, MN

Nipple sparing mastectomy with intra operative radiotherapy
Jean-Yves Petit
European Institute of Surgical Oncology
Milan, ITALY

3:15-5:30 GENERAL SESSION 4 – Exhibit Hall D
3:15 41. FinXX final 5-year analysis: Results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer
Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Bono P, Lindman H, On behalf of the FinXX Study Investigators. Helsinki University Central Hospital, Finland, Tampere University Hospital, Finland, Turku University Central Hospital, Finland, Oulu University Hospital, Oulu, Finland, Kanta-Hame Central Hospital, Hamenlinna, Finland, Gavle Hospital, Gavle, Sweden, Kuopio University Hospital, Kuopio, Finland, Uppsala University Hospital, Sweden.

3:30 42. First efficacy results of a randomized, open-label, phase III study of adjuvant Doxorubicin plus Cyclophosphamide followed by Docetaxel with or without Capecitabine in high-risk early breast cancer

3:45 43. Ten-year follow-up analysis of the BICR 001 trial confirms superior DFS and OS benefit of adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in women with operable node-positive breast cancer
Martin M, Mackey J, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Glasper J, Juhos E, Wardley A, Fernander T, Hainsworth J, Coleman R, Modiano M, Vinholes J, Pinter T, Childs B, Roessner M, Wilson V, Rupin M, Vogel C, on behalf of the BCRG 001 Investigators. Cross Cancer Institute, Edmonton, Canada, GECAM, Madrid, Spain, Cancer Centre, Warsaw, Poland, Cancer Center, Krakow, Poland, Centre Leon Berard, Lyon, France, Saskatoon Cancer Centre, SK, Canada, TARI, Los Angeles, National Institute of Oncology, Budapest, Hungary, Christie Hospital, Manchester, United Kingdom, Stockholm Soder Hospital, Sweden, The Sarah Cannon Cancer Center, Nashville, TN, Weston Park Hospital, Sheffield, United Kingdom, Arizona Clinical Research Center, Tucson, Clinica de Oncologia de Porto Alegre, Porto Alegre, Brazil, Petz Aladar County Hospital, Gyor, Hungary, Sanofi-Aventis, Bridgewater, CIRO, Edmonton, Canada, Lynn Cancer Institute, Boca Raton.

4.45 SECRAB: The optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) in early breast cancer (EBC), results of a UK multicentre prospective randomised trial
Fernando IN, Bowden SJ, Buckley L, Grieve R, Spooner D, Agrawal RK, Brunt AM, Stockdale AD, Chum ML, Stevens A, Marshall A, Canney P. University Hospitals Birmingham NHS Foundation Trust, United Kingdom, University of Birmingham, United Kingdom, University Hospital, Coventry, United Kingdom, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom, University Hospitals North Staffordshire, Stoke-on-Trent, United Kingdom, New Cross Hospital, Wolverhampton, United Kingdom, University of Warwick, United Kingdom, Beaton West of Scotland Cancer Centre, Glasgow, United Kingdom.

4:15 Adjuvant treatment with Zoledronic Acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04)
Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell R. Weston Park Hospital, Sheffield, United Kingdom, University of Leeds, United Kingdom. AZURE (BIG 01/04) Investigators.

4:30 44. neoadjuvant chemotheraphy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)

4:45 45. Promoter CpG Methylation of BRCA1 predicts sensitivity to PARP inhibitors in breast cancer
Veerick J, Ropper S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez I, Herman JG, Tjan-Heijnen VC, Esteller M. Bellvitge Institute for Biomedical Research, Barcelona, Spain, Maastricht University Medical Centre, Netherlands, Spanish National Cancer Research Centre, Madrid, Spain, Johns Hopkins University School of Medicine, Baltimore, MD.

4:50 46. Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score

4:55 47. Promoter CpG Methylation of BRCA1 predicts sensitivity to PARP inhibitors in breast cancer
Veerick J, Ropper S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez I, Herman JG, Tjan-Heijnen VC, Esteller M. Bellvitge Institute for Biomedical Research, Barcelona, Spain, Maastricht University Medical Centre, Netherlands, Spanish National Cancer Research Centre, Madrid, Spain, Johns Hopkins University School of Medicine, Baltimore, MD.

5:00 48. Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score

5:15 49. TBA
5:30-7:30  POSTER DISCUSSION 5 & RECEPTION – Ballroom A
Endocrine Resistance  501-511
5:30-7:30  POSTER DISCUSSION 6 & RECEPTION – Ballroom B
Local and Axillary Treatment  601-610
5:30-7:30  POSTER SESSION 3 & RECEPTION – Exhibit Halls A-B (#3001-31??)
Detection/Diagnosis
Circulating Tumor Cells  3001-3016
Micrometastases  3017-3021
CirculatingMarkers  3022-3028
Prognosis and Response Predictions
PrognosticFactors and Biomarkers – Preclinical  3029-3044
Biomarkers – Methods  3045-3053
Prognosis and Response Predictions – Other  3054-3056
Risk, Epidemiology, and Prevention
Epidemiology – Genetic and Molecular  3057-3064
Ethnic/Racial Aspects  3065-3073
Social, Behavioral, Economic, and Outreach Studies
Research Resources  3074-3076
Disparities and Barriers to Care  3077-3084
Advocacy  3085
Treatment
Adjuvant Therapy – Targeted  3086-3088
Advanced Therapy – Targeted  3089-3097
Alternative Therapies  3098-3101
Surgery  3102-3120
Tumor Biology
Novel/Emerging Therapeutic Targets  3121-3145
Novel Models  3146
Oncogenes / Tumor Suppressor Genes  3147-3161
Tumor Heterogeneity / Molecular Subclassification  3162-3168
SATURDAY, DECEMBER 11, 2010
7:00-9:00  POSTER DISCUSSION 7 & CONTINENTAL BREAKFAST – Ballroom A
Markers in Neoadjuvant Therapy  701-710
7:00-9:00  POSTER DISCUSSION 8 & CONTINENTAL BREAKFAST – Ballroom B
Survivorship Research  801-810
7:00-9:00  POSTER SESSION 4 & CONTINENTAL BREAKFAST – Exhibit Halls A-B (#4001-4173)
Detection/Diagnosis
Screening and Detection  4001-4013
Breast Imaging – Mammography  4014-4015
Breast Imaging – MRI  4016-4027
Radiology  4028
Prognosis and Response Predictions
Prognostic Factors and Biomarkers – Clinical Testing and Validation I  4029-4068
Risk, Epidemiology, and Prevention
Familial Breast Cancer - Genetic Testing  4069-4079
Treatment
Adjuvant Endocrine Therapy  4080-4093
Advanced Endocrine Therapy  4094-4099
Radiation Therapy  4100-4115
Breast Conservation  4116-4127
Tumor Biology
Immunology and Immunotherapy  4128-4135
Hormonal Factors and Receptors  4136-4158
Tumor Microenvironment  4159-4166
Growth Factors  4167-4172
Tumor Biology – Other  4173
9:00-9:30  PLENARY LECTURE 3 – Exhibit Hall D
The Upside of Irrationality
Dan Ariely, PhD
Duke University
Durham, NC
9:30-11:15  GENERAL SESSION 5 – Exhibit Hall D
51. Prospective long term outcomes for patients with micro- and macro-positive sentinel nodes: NSABP B-32 sentinel node trial
9:45 52. Latrogenic displacement of tumor cells to the sentinel node after surgical excision biopsy in primary breast cancer
Tvetcjoke TF, Jensen MB, Kromn N, Baloev E. Copenhagen University Hospital, Copenhagen, Denmark, Danish Breast Cancer cooperative Group, Copenhagen, Denmark, Herlev Hospital, Herlev, Denmark.
10:00 53. Is manual lymph drainage applied after axillary lymph node dissection for breast cancer effective to prevent arm lymphoedema? A randomised controlled trial
10:15 54. Synthetic-lethality of triple-negative breast cancers via the MYC oncogene pathway
Goga A, Horuchi D, Kusidr L, Chandrani S, Lenburg ME, Gonzalez-Angulo AM, Huskey NE, Creasman JW, Davis SE, Mills GB, Esserman LJ. University of California, San Francisco, Boston University School of Medicine, M.D. Anderson Cancer Center.
10:45 55. Identification of a clinically relevant gene signature in triple negative and basal like breast cancer
Rody A, Kar M, Liedkje C, Puszta L, Ruckhaberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtich U, Kaufmann M. Goethe-University, Frankfurt, Germany, University of Muenster, Germany, University of Texas M.D. Anderson Cancer Center, Houston, Ludwig-Maximilians University, Munich, Germany, J. Gutenberg-University, Mainz, Germany, University of Hamburg, Germany.
10:55 56. Steroid hormone regulation of mammary stem cell function
Lindeman GJ, Asselin-Labat M-L, Vaillant F, Sheridan J, Davis JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth G, Martin JT, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia, The Royal Melbourne Hospital, Melbourne, VIC, Australia, Prince Henry’s Institute of Medical Research, Clayton, VIC, Australia, Nagahama Institute for Biochemical Science, Nagahama, Shiga, Japan, St Vincent’s Institute, Fitzroy, VIC, Australia.
57. Estrogen receptor alpha negative (ER-) breast cancer stem cells in ER+ cell lines and primary cancers are enriched by Tamoxifen therapy
O’Brien CS, Howell SJ, Gandhi A, Gee J, Lykkesfeldt A, Nicholson RI, Clarke RB. University of Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom, University Hospital of South Manchester, Manchester, United Kingdom, University of Cardiff, Wales, United Kingdom, Danish Cancer Society, Copenhagen, Denmark.

1:15-12:00 William L. McGuire Memorial Lecture – Exhibit Hall D
Supported by GlaxoSmithKline
What Would Bill Do? Channeling Your Inner McGuire
George W. Sledge, Jr., MD
Indiana University Simon Cancer Center
Indianapolis, IN

3:00-5:30 General Session 6 – Exhibit Hall D

61. Menopausal hormone therapy influence on cancer incidence and related cancer mortality in the Women’s Health Initiative Randomized Trials
Chlebowski RT. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.

62. 313 patients with breast cancer during pregnancy - results from a prospective and retrospective registry (GBG-20/BIG02-03)
Loibl S, Amant F, Kaufmann M, Ring A, Sikytn H, Giemek J, Fehm T, Bontembal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G. German Breast Group, Neu-Isenburg, Germany, UZ Leuven Campus Gasthuisberg, Belgium, Universitäts-Frauenklinik Fankfurt aM, Germany, Royal Sussex County Hospital, Brighton, United Kingdom, Cancer Center and Institute of Oncology, Warsaw, Poland, Universitäts-Frauenklinik Tubingen, Germany, Enasmus Medical Center, Rotterdam, Netherlands, Klinikum der Universität München, Germany, Klinikum der Universität Münster, Germany, Elisabeth Krankenhaus-Kassel, Kassel, Germany.

63. Compliance with Mammographic Screening Guidelines from an Administrative Claims Database
Subar M, Lust SA, Lin W. Medco Research Institute, Franklin Lakes, NJ.

64. Association between prescription co-payment amount and compliance with adjuvant aromatase inhibitor therapy in women with early stage breast cancer

65. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients

66. High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients

67. Establishment and Characterization of Human Luminal Breast Cancer Xenografts
5:30-7:30  POSTER DISCUSSION 9 & RECEPTION – Ballroom A
Obesity and Breast Cancer 901-908

5:30-7:30  POSTER DISCUSSION 10 & RECEPTION – Ballroom B
HER-2 and ER Testing 951-960

5:30-7:30  POSTER SESSION 5 & RECEPTION - Exhibit Halls A-B (#5001-5169)
Detection/Diagnosis
Molecular, Functional, and Novel Imaging 5001-5016
Breast Imaging - Other Methods 5017-5030
Detection / Diagnosis – Other 5031-5034

Social, Behavioral, Economic and Outreach Studies
Quality of Life - Supportive Care 5035-5051
Palliation and Support (Pain Management) 5052

Treatment
Novel Targets and Targeted Agents 5053-5076
Signal Transduction Inhibitors 5077-5080
Her2-Targeted Therapy 5081-5114
Treatment – Other 5115-5123

Tumor Biology
Endocrine Therapy and Resistance 5124-5149
Metabolism and Breast Cancer 5150-5155
Etiology / Carcinogenesis 5156-5158
Gene Therapy 5159
Genetics - Germline Changes 5160-5163
Genetics - Somatic Changes 5164-5169

8:30-10:30  YEAR IN REVIEW
Moderator: C. Kent Osborne, MD, Baylor College of Medicine, Houston, TX
Advances in basic breast cancer research
Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX
Translational breast cancer research
Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM
Early breast cancer
Aron Goldhirsch, MD
European Institute of Oncology
Milan, ITALY
Progress in advanced breast cancer
Lisa A. Carey, MD
University of North Carolina
Chapel Hill, NC
10:30  ADJOURNMENT

SUNDAY, DECEMBER 12, 2010
7:00-8:30  POSTER SESSION 6 & CONTINENTAL BREAKFAST – Exhibit Hall C (#6001-6174)
Detection/Diagnosis
Diagnostic Pathology 6001-6020
Biopsy Techniques 6021-6022

Prognosis and Response Predictions
Prognostic Factors and Biomarkers - Clinical Testing and Validation II 6023-6061

Risk Factors, Epidemiology, and Prevention
Risk Factors and Modeling 6062-6073

Social, Behavioral, Education, and Outreach Studies
Education 6074-6078
Doctor-Patient Communication 6079-6082

Treatment
Anti-angiogenic Therapy 6083-6093
Antibody-Based Regimens 6094-6096
New Drugs and Treatment Strategies 6097-6117

Tumor Biology
Molecular Profiles 6118-6133
Genomics 6134-6139
Tumor Progression, Invasion, and Metastasis 6140-6174